Want to see XBIO full AI Analyst Report?
XBIO Stock Chart & Stats
$2.64
-$0.14(-5.30%)
At close: 4:00 PM EDT
$2.64
-$0.14(-5.30%)
Day’s Range― - ―
52-Week Range$1.90 - $13.93
Previous Close$2.64
Volume3.06K
Average Volume (3M)1.70M
Market Cap
$5.81M
Enterprise Value-$1.21
Total Cash (Recent Filing)$7.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding2,291,056
10 Day Avg. Volume5,053,508
30 Day Avg. Volume1,695,238
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$3.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure and positive equity provide structural financial flexibility, lowering insolvency and refinancing risk. This durability supports continued R&D and partnering options without near-term interest burden, preserving optionality while the firm pursues clinical and licensing milestones.
High Gross Margins With Revenue GrowthSustained high gross margins (~75%) paired with TTM revenue growth indicate the underlying offerings have favorable economics and growing demand. Over the medium term this improves the odds of reaching operating leverage as revenues scale or costs are better controlled, supporting longer-term margin recovery.
Management Alignment Via Equity AwardIssuing restricted stock to interim leadership aligns management incentives with shareholders and helps retain key executives through execution of clinical and business-development milestones. This structural governance step can improve execution continuity and reduce leadership turnover risk while pursuing partnerships.
Bears Say
Sustained UnprofitabilityDeep negative net margins (TTM ~-70%) and persistent operating losses signal structural profitability issues. Without durable margin improvement or material new revenue streams, the company will likely need external funding, which can dilute shareholders and constrain long-term value creation.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow reduces financial runway and raises reliance on financings or partnerships to fund R&D and trials. Even with lower peak burn versus prior years, persistent outflows create structural funding risk until operations approach breakeven or non-dilutive income is secured.
Erosion Of Shareholder EquityMaterial decline in equity and strongly negative ROE reflect ongoing capital erosion from losses. This reduces the balance-sheet cushion against shocks, limits capacity to raise non-dilutive capital, and signals that current capital allocation has not yet delivered positive returns for shareholders.
Xenetic Biosciences News
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $1.90 and its highest was $13.93 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $5.81M.
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is Aug 07, 2026 which is in 5 days.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on May 13, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,291,056 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -$0.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.159%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Technical Analysis
Ownership Overview
4.36% Insiders
0.87% Mutual Funds
0.12% Other Institutional Investors
94.09% Public Companies and
Individual Investors